Cargando…

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors have anti-tumor effects against renal cell carcinoma, pancreatic neuroendocrine cancer and breast cancer. In this study, we analyzed the antitumor effects of mTOR inhibitors in small cell lung cancer (SCLC) cells and sought to clarify the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Masaru, Seike, Masahiro, Noro, Rintaro, Soeno, Chie, Sugano, Teppei, Takeuchi, Susumu, Miyanaga, Akihiko, Kitamura, Kazuhiro, Kubota, Kaoru, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414307/ https://www.ncbi.nlm.nih.gov/pubmed/25884680 http://dx.doi.org/10.1186/s12885-015-1202-4

Ejemplares similares

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
por: CAO, MENGRU, et al.
Publicado: (2012)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer
por: Shimizu, Masamitsu, et al.
Publicado: (2022)

Metformin blocks MYC protein synthesis in colorectal cancer via mTOR‐4EBP‐eIF4E and MNK1‐eIF4G‐eIF4E signaling
por: Shen, Peng, et al.
Publicado: (2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
por: Fukuizumi, Aya, et al.
Publicado: (2015)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
por: Sugano, Teppei, et al.
Publicado: (2019)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
por: Nakamichi, Shinji, et al.
Publicado: (2018)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

The Role of mTOR and eIF Signaling in Benign Endometrial Diseases
por: Driva, Tatiana S., et al.
Publicado: (2022)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
por: Alain, Tommy, et al.
Publicado: (2012)

eIF4E3 forms an active eIF4F complex during stresses (eIF4F(S)) targeting mTOR and re-programs the translatome
por: Weiss, Benjamin, et al.
Publicado: (2021)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
por: Romagnoli, Alice, et al.
Publicado: (2021)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
por: Satheesha, Sampoorna, et al.
Publicado: (2011)

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy
por: Ramírez-Valle, Francisco, et al.
Publicado: (2008)

Temporal and spatial regulation of translation in the mammalian oocyte via the mTOR–eIF4F pathway
por: Susor, Andrej, et al.
Publicado: (2015)

A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension
por: Wang, Ai-ping, et al.
Publicado: (2015)

eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway
por: Sun, Liping, et al.
Publicado: (2021)

Requirement for the eIF4E Binding Proteins for the Synergistic Down-Regulation of Protein Synthesis by Hypertonic Conditions and mTOR Inhibition
por: Clemens, Michael J., et al.
Publicado: (2013)

Sensitivity of Global Translation to mTOR Inhibition in REN Cells Depends on the Equilibrium between eIF4E and 4E-BP1
por: Grosso, Stefano, et al.
Publicado: (2011)

eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis
por: Ruan, Hang, et al.
Publicado: (2020)

Regulation of Translation by TOR, eIF4E and eIF2α in Plants: Current Knowledge, Challenges and Future Perspectives
por: Sesma, Ane, et al.
Publicado: (2017)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rn7noo3fiu2sag4h2jo3kjut5e